Moderna's stock fell nearly 60% last year as sales of its COVID-19 vaccine crashed from their peak during the pandemic and ...
Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.
Moderna (NASDAQ:MRNA) is scheduled to announce Q4 earnings results on Friday, February 14th, before market open. Analysts expect a loss of $2.73 on revenue of $941.14M (-66.5% Y/Y). According to BofA ...
Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. MRNA has guided for 2025 revenues of $1.5B-$2.5B which doesn't seem to have ...
Ohio is one of many states experiencing a quad-demic of infections. These 4 viral infections are COVID-19, influenza (flu), ...
Moderna's RSV vaccine earned approval last May, but sales haven't gotten off the ground yet. The biotech company expects to lose money again in 2025, but operating expenses are declining.
Looking ahead, BofA cut its 2025 and 2026 revenue forecasts by 18% and 15%, respectively. While negative EPS projections ...
Through the first nine months of 2024, Moderna's revenue of $2.3 billion represents a 44% decline year over year. This figure includes a mere $10 million in sales of the new RSV vaccine following ...